Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
## Retatrutide Cost and Availability in 2026: Current Pricing Landscape Retatrutide, the triple agonist (GIP/GLP-1/glucagon) that produced up to 24.2% weight loss in Phase 2 trials, remains in Phase 3 clinical development as of July 2026
Designed to protect up to OEB 5, the highest containment level Nanogramlevel exposure protection for highly potent compounds Proven fit for highdemand GLP1 production environments Commercially, were seeing strong demand for DoverPacs in GLP1 applications as manufacturers scale faster and push for safer, more flexible containment solutions
The key difference is the preservative
We have partnered with the CDC to offer a group-based program that has been proven to help participants lose weight, adopt better eating habits, and achieve the recommended amount of physical activity
US$ 27.83
US$ 22.96
US$ 29.40
US$ 23.85
US$ 24.71
US$ 26.24
